{
    "organizations": [],
    "uuid": "4936a72cc2428f57e822710c2857c73313c23261",
    "author": "Allison Prang",
    "url": "https://www.wsj.com/articles/axovant-will-no-longer-develop-lead-dementia-drug-1515430108",
    "ord_in_thread": 0,
    "title": "Axovant Will No Longer Develop Lead Dementia Drug",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Axovant Sciences Ltd. lost half of its market value Monday after it said a drug once intended to treat Alzheimer’s disease didn’t meet certain goals in recent studies.\nSwitzerland-based Axovant, whose shares fell 50% to $2.71 in morning trading, said it would no longer develop its main drug, known as intepirdine, that analysts once thought could top $2 billion in annual sales.\n“Based... ",
    "published": "2018-01-08T19:48:00.000+02:00",
    "crawled": "2018-01-09T09:42:15.817+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "axovant",
        "science",
        "lost",
        "half",
        "market",
        "value",
        "monday",
        "said",
        "drug",
        "intended",
        "treat",
        "alzheimer",
        "disease",
        "meet",
        "certain",
        "goal",
        "recent",
        "study",
        "axovant",
        "whose",
        "share",
        "fell",
        "morning",
        "trading",
        "said",
        "would",
        "longer",
        "develop",
        "main",
        "drug",
        "known",
        "intepirdine",
        "analyst",
        "thought",
        "could",
        "top",
        "billion",
        "annual",
        "sale",
        "based"
    ]
}